Sugi Predict

Sugi Predict / Compounds / SCHEMBL333559

SCHEMBL333559

SCHEMBL333559

O=C(CBr)Nc1cccc(Cl)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 6/20 0.65
▸ KMT2A Q03164 6/20 0.65
▸ ALDH1A1 P00352 5/20 0.65
▸ MAPT P10636 4/20 0.65
▸ LMNA P02545 3/20 0.65
▸ HTT P42858 2/20 0.65
▸ HSD17B10 Q99714 1/20 0.60
▸ KCNJ5 P48544 1/20 0.60
▸ KCNJ3 P48549 1/20 0.60
▸ RAB9A P51151 3/20 0.59
▸ NPC1 O15118 2/20 0.59
▸ EPHX2 P34913 1/20 0.57
▸ HTR3E A5X5Y0 1/20 0.57
▸ HTR3B O95264 1/20 0.57
▸ HTR3A P46098 1/20 0.57
▸ HTR3D Q70Z44 1/20 0.57
▸ HTR3C Q8WXA8 1/20 0.57
▸ HPGD P15428 1/20 0.56
▸ MAOA P21397 1/20 0.56
▸ MAOB P27338 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29748804 1.00 MEN1 (0.65) MEN1KMT2AALDH1A1MAPTLMNA
SCHEMBL31590348 0.88 MEN1 (0.59) MEN1KMT2AALDH1A1MAPTLMNA
SCHEMBL6409908 0.88 MEN1 (0.59) MEN1KMT2AALDH1A1MAPTLMNA
SCHEMBL5141417 0.87 MEN1 (0.71) MEN1KMT2AALDH1A1MAPTLMNA
SCHEMBL21765844 0.87 POLB (0.56) MEN1KMT2AALDH1A1MAPTLMNA
SCHEMBL7646371 0.84 MEN1 (0.67) MEN1KMT2AALDH1A1MAPTLMNA
SCHEMBL30475544 0.84 MEN1 (0.67) MEN1KMT2AALDH1A1MAPTLMNA
SCHEMBL4004381 0.84 MEN1 (0.67) MEN1KMT2AALDH1A1MAPTLMNA
SCHEMBL9403861 0.82 MEN1 (0.65) MEN1KMT2AALDH1A1MAPTLMNA
SCHEMBL4873093 0.82 MEN1 (0.65) MEN1KMT2AALDH1A1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12371429-B2 Antibiotic resistance-modifying tricyclic heteroaryl compounds and uses thereof RECREO PHARMACEUTICALS LLC (US) 2025-07-29 — — US disclosed
CN-114716344-B 2- ((2-acetamidophenyl) amino) acetamido compound and preparation method and application thereof 湖南科技大学 2023-12-22 — — CN disclosed
CN-117003744-A Five-membered and six-membered compound, intermediate, preparation method, composition and application 厦门市博瑞来医药科技有限公司 2023-11-07 — — CN disclosed
CN-110734417-B 2-butenolide acetamide compound and preparation method and application thereof 南开大学 2022-09-30 — — CN disclosed
CN-112341396-B Novel monoacylglycerol esterase inhibitor and preparation method and application thereof 四川大学华西医院 2022-07-26 — — CN disclosed
CN-114716344-A 2- ((2-acetamidophenyl) amino) acetyl arylamine compound and preparation method and application thereof 湖南科技大学 2022-07-08 — — CN disclosed
EP-3836919-A1 1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOLE DERIVATIVE COMPOUNDS AND USES THEREOF Recreo Pharmaceuticals Inc. (US) 2021-06-23 — — EP disclosed
US-20210163479-A1 1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOLE DERIVATIVE COMPOUNDS AND USES THEREOF RECREO PHARMACEUTICALS LLC (US) 2021-06-03 — — US disclosed
CN-112654354-A 1,3,4, 9-tetrahydro-2H-pyrido [3,4-b ] indole derivative compound and application thereof 菲尼克思药业股份有限公司 2021-04-13 — — CN disclosed
CN-112341396-A Novel monoacylglycerol esterase inhibitor and preparation method and application thereof 四川大学华西医院 2021-02-09 — — CN disclosed
EP-1077701-A1 ANTI-VIRAL COMPOUNDS ELI LILLY AND COMPANY (US) 2001-02-28 — — EP disclosed
WO-1999059587-A1 ANTI-VIRAL COMPOUNDS ELI LILLY AND COMPANY (US) 1999-11-25 — — WO disclosed
US-5925651-A Inhibitors of farnesyl-protein transferase MERCK & CO., INC. (US) 1999-07-20 — — US disclosed
EP-0891335-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE Merck & Co., Inc. (US) 1999-01-20 — — EP disclosed
WO-1997036877-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 1997-10-09 — — WO disclosed
US-5223623-A 2-substituted-1(4)-aryl piperazines and the process for their preparation SCHERING AG (DE) 1993-06-29 — — US disclosed
EP-0491709-A1 2-SUBSTITUTED-1(4)-ARYL PIPERAZINES AND THE PROCESS FOR THEIR PREPARATION SCHERING AKTIENGESELLSCHAFT (DE) 1992-07-01 — — EP disclosed
US-5051422-A 2-substituted-1(4)-aryl piperazines and the process for their preparation SCHERING AG (DE) 1991-09-24 — — US disclosed
WO-1991004250-A1 2-SUBSTITUTED-1(4)-ARYL PIPERAZINES AND THE PROCESS FOR THEIR PREPARATION SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) 1991-04-04 — — WO disclosed
US-4102924-A REACTING ACYLAMINO-ARYLS WITH HALO-ARYLS BAYER AKTIENGESELLSCHAFT (DE) 1978-07-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12371429-B2 Antibiotic resistance-modifying tricyclic heteroaryl compounds and uses thereof CBR3, CBR1, CYP2B6 MEN1 1968/4885KMT2A 1544/4885ALDH1A1 1459/4885
US-20210163479-A1 1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOLE DERIVATIVE COMPOUNDS AND USES THEREOF H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNA1, FOXM1 MEN1 1942/4885KMT2A 1984/4885ALDH1A1 767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.